Soleno Therapeutics, Inc. (NASDAQ:SLNO) Insider Kristen Yen Sells 5,270 Shares

Soleno Therapeutics, Inc. (NASDAQ:SLNO) insider Kristen Yen sold 5,270 shares of Soleno Therapeutics stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $47.58, for a total transaction of $250,746.60. Following the transaction, the insider now directly owns 90,008 shares of the company’s stock, valued at $4,282,580.64. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Kristen Yen also recently made the following trade(s):

• On Monday, August 5th, Kristen Yen sold 5,017 shares of Soleno Therapeutics stock. The shares were sold at an average price of $45.77, for a total transaction of $229,628.09.
• On Monday, July 1st, Kristen Yen sold 2,170 shares of Soleno Therapeutics stock. The shares were sold at an average price of $41.54, for a total transaction of $90,141.80.

Soleno Therapeutics Trading Up 5.1 %

Shares of NASDAQ:SLNO traded up $2.39 during trading on Friday, hitting $48.95. 475,543 shares of the company’s stock were exchanged, compared to its average volume of 423,476. Soleno Therapeutics, Inc. has a 1-year low of $3.69 and a 1-year high of $53.82. The firm has a 50-day moving average price of $46.13 and a two-hundred day moving average price of $44.55. The firm has a market cap of $1.64 billion, a P/E ratio of -18.26 and a beta of -1.39.

Soleno Therapeutics (NASDAQ:SLNO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.63) by $0.06. As a group, research analysts predict that Soleno Therapeutics, Inc. will post -2.36 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Amalgamated Bank bought a new position in Soleno Therapeutics during the 2nd quarter worth approximately $31,000. Victory Capital Management Inc. boosted its stake in Soleno Therapeutics by 26.3% during the 2nd quarter. Victory Capital Management Inc. now owns 10,727 shares of the company’s stock worth $438,000 after acquiring an additional 2,236 shares during the last quarter. Sei Investments Co. boosted its stake in Soleno Therapeutics by 22.0% during the 1st quarter. Sei Investments Co. now owns 12,577 shares of the company’s stock worth $538,000 after acquiring an additional 2,264 shares during the last quarter. California State Teachers Retirement System boosted its stake in Soleno Therapeutics by 33.8% during the 1st quarter. California State Teachers Retirement System now owns 13,780 shares of the company’s stock worth $590,000 after acquiring an additional 3,481 shares during the last quarter. Finally, Swiss National Bank boosted its stake in Soleno Therapeutics by 32.0% during the 1st quarter. Swiss National Bank now owns 30,100 shares of the company’s stock worth $1,288,000 after acquiring an additional 7,300 shares during the last quarter. Institutional investors own 97.42% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on SLNO shares. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Soleno Therapeutics in a research report on Wednesday, July 31st. Robert W. Baird started coverage on shares of Soleno Therapeutics in a research report on Friday, May 10th. They issued an “outperform” rating and a $72.00 price objective for the company. Baird R W upgraded shares of Soleno Therapeutics to a “strong-buy” rating in a research report on Friday, May 10th. Finally, Oppenheimer raised their price objective on shares of Soleno Therapeutics from $59.00 to $65.00 and gave the company an “outperform” rating in a research report on Monday, August 12th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Soleno Therapeutics has a consensus rating of “Buy” and an average price target of $66.67.

Soleno Therapeutics Company Profile

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.